Sakshi Kharchan*
Payal Tighare
- Overview Of Dermatological Inflammatory Disorders
Dermatological inflammatory disorders represent a broad category of skin diseases characterized by clinical manifestations such as erythema, edema, pruritus, pain, and impairment of the protective epidermal barrier [1]. These conditions arise from complex interactions between environmental factors, immune responses, and genetic predisposition. Common inflammatory skin disorders include atopic dermatitis, psoriasis, acne vulgaris, eczema, and chronic non-healing wounds. Although most of these disorders are not considered life-threatening, they can considerably affect patients’ quality of life due to persistent symptoms, cosmetic concerns, and frequent recurrence [2].
The pathophysiology of skin inflammation involves the activation of keratinocytes along with immune cells such as macrophages, dendritic cells, and mast cells. Upon activation, these cells release a variety of pro-inflammatory mediators including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), prostaglandins, and leukotrienes [3]. These inflammatory molecules promote vasodilation, increase vascular permeability, and facilitate the migration of leukocytes to the affected site, which ultimately leads to visible redness, swelling, and irritation of the skin.
Prolonged or uncontrolled activation of inflammatory signaling pathways, particularly the nuclear factor-kappa B (NF-κB) pathway, plays a significant role in the progression of chronic skin disorders. Continuous stimulation of these pathways can result in persistent tissue inflammation, epidermal hyperproliferation, and structural damage to skin tissues, thereby aggravating the severity and duration of dermatological conditions [4].
10.5281/zenodo.19482388